Bristol Myers Squibb stock

Bristol‑Myers Squibb stock

A concise guide to the publicly traded equity of Bristol‑Myers Squibb Company (ticker: BMY), listed on the New York Stock Exchange. This article covers ticker and listing details, price performance, dividends, corporate events, investor resources, risks, trading mechanics and primary sources for live quotes and filings. Read on to get clear, verifiable facts about bristol myers squibb stock and where to find up‑to‑date market data and company disclosures.

As of Jan 25, 2026, according to AP and Benzinga market reports, Bristol‑Myers Squibb was trading in the mid‑$50s per share with daily volumes around 1.9–2.2 million shares — see "References and data sources" below for cited sources.

Company overview

Bristol‑Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for serious diseases. The company's business lines include specialty medicines across oncology, hematology, immunology, cardiovascular and fibrosis therapies. Flagship commercial products have included medicines such as Eliquis (cardiovascular), Opdivo (immuno‑oncology; historically marketed via partnerships) and other specialty oncology and immunology treatments. The company is headquartered in New York, U.S., with research, development and manufacturing operations globally.

This business context is the foundation for evaluating bristol myers squibb stock: drug approvals, patent expirations, pipeline readouts and M&A activity can all materially affect the company’s revenue, margins and investor expectations.

Ticker symbol and listing

• Ticker symbol: BMY (common stock)
• Primary exchange: New York Stock Exchange (NYSE)
• Trading currency: U.S. dollars (USD)
• Initial public listing: Bristol‑Myers (legacy) and Squibb names date to the 20th century; modern BMY common stock has traded on the NYSE for many decades following corporate mergers and reorganizations.
• Cross‑listings / equivalents: BMY trades primarily on the NYSE; U.S. ADRs or local market equivalents are not typical for a U.S.‑headquartered NYSE listing. For local currency access or brokerage wrappers, consult your local broker.

Investors monitoring bristol myers squibb stock should track the NYSE listing and authoritative company investor communications for any changes in capital structure or secondary listings.

Stock profile and trading information

Below are the commonly tracked trading data points that investors and analysts use when monitoring bristol myers squibb stock. Because market values change daily, use the listed sources (company IR, Yahoo Finance, CNBC, MarketWatch, Google Finance, Morningstar) for real‑time or delayed updates.

• Market capitalization: a frequently reported metric; check Yahoo Finance or Morningstar for the live market cap for bristol myers squibb stock.
• Shares outstanding and float: published in SEC filings (Form 10‑Q / 10‑K) and displayed on major finance data sites.
• Average daily trading volume: typically in the low millions of shares for BMY; as of Jan 25, 2026 AP and Benzinga listings reported intraday volumes near 1.9–2.2 million shares on sample trading sessions.
• Trading hours: Regular NYSE session (09:30–16:00 ET). Pre‑market and after‑hours trades may be available through many brokers with different liquidity.
• Quote delays and data providers: Most free finance portals provide delayed quotes (commonly 15–20 minutes). Paid data feeds or brokerage platforms provide real‑time quotes.
• Primary data providers: company investor relations pages and SEC filings are primary. Secondary providers include Yahoo Finance, Google Finance, CNBC, MarketWatch and Morningstar for consolidated charts and metrics.

Real‑time and delayed quotes

Investors typically obtain quotes and charts for bristol myers squibb stock from the following sources:

• Company investor relations pages (official filings, press releases, earnings calendars)
• Yahoo Finance (detailed quotes, historical data, basic fundamentals)
• Google Finance (quick quotes and charting)
• CNBC and MarketWatch (market commentary and earnings coverage)
• Retail broker platforms (order execution, typically provide real‑time quotes)
• Mobile trading apps and market data vendors for advanced charting and alerts

Note: Free public portals often show delayed quotes (commonly 15–20 minutes). For trade execution and definitive pricing, use your broker’s live feed. Always check the "as of" timestamp on any quote. For bristol myers squibb stock, company filings and the NYSE official tape are the authoritative record of corporate actions and trade data.

Historical price performance

When summarizing historical performance for bristol myers squibb stock, investors often look at multiple periods:

• Intraday price action: useful for traders monitoring news or earnings day moves.
• Year‑to‑date (YTD): measures performance since the start of the calendar year.
• 1‑year return: captures recent momentum and major events in the last 12 months.
• 3‑year and 5‑year returns: contextualize longer‑term trends including product launches, patent expirations and large M&A events.

Key price milestones to highlight when presenting historical data:

• 52‑week high and 52‑week low (commonly listed on finance sites). These points illustrate the trading range and volatility for bristol myers squibb stock over the most recent year.
• Multi‑year trends tied to business events (for example, the Celgene acquisition or major product approvals and patent expirations) that drove shifts in valuation.

How to present charts and historical tables:

• Use candlestick or line charts for 1‑day, 1‑month, 6‑month, 1‑year and multi‑year views.
• Pair price charts with volume bars and key annotations (earnings release dates, FDA decisions, M&A announcements).
• Source the chart data from Yahoo Finance, Google Finance or the company’s historical stock price page and always timestamp the snapshot (e.g., "Data as of Jan 25, 2026").

As of Jan 25, 2026, market reports showed bristol myers squibb stock trading in the mid‑$50s per share (see "References and data sources" for citations). Historical returns should be calculated using official daily close prices from the chosen data provider.

Dividend policy and history

Bristol‑Myers Squibb has historically returned cash to shareholders via quarterly dividends. Key items investors track when assessing bristol myers squibb stock on the dividend front:

• Dividend policy: frequency (quarterly), historical consistency and any guidance from management.
• Recent dividend yield levels: dividend yield = annual dividend per share / current share price. Yield fluctuates with stock price.
• Payment frequency and dates: most large U.S. pharmaceutical companies pay dividends quarterly; consult company dividend press releases or investor relations for record and ex‑dividend dates.
• Historical dividend changes: increases, decreases or special dividends are material events and are disclosed in dividend announcements and earnings releases.

Dividend yield is commonly used by income‑oriented investors in evaluating bristol myers squibb stock, but it should be considered alongside payout ratio, free cash flow and earnings stability. For authoritative dividend history and upcoming dates, refer to the company IR site and SEC filings.

Financials and valuation metrics

When valuing bristol myers squibb stock, investors and analysts rely on a standard toolkit of financial metrics and statements.

Key metrics to review:

• Revenue and revenue growth: top‑line sales, growth rates and segment breakdowns.
• Net income and profit margins: operating and net margins indicate profitability trends.
• Earnings per share (EPS): basic and diluted EPS on GAAP and adjusted (non‑GAAP) bases.
• Price‑to‑earnings (P/E) ratio: commonly reported when EPS is positive; if EPS is negative, P/E is not meaningful.
• EV/EBITDA: enterprise value to EBITDA for capital‑structure‑neutral comparison across peers.
• Free cash flow: operating cash flow less capital expenditures — important for dividend sustainability and buybacks.
• Balance sheet highlights: cash and short‑term investments, total debt, debt maturities and key liquidity ratios.

Primary sources for up‑to‑date financial statements and metrics are the company’s SEC filings (Form 10‑Q and 10‑K), company investor relations releases and reputable data providers such as Morningstar, Yahoo Finance and Morningstar. For bristol myers squibb stock, always cross‑check adjusted figures with management disclosures and SEC footnotes to fully understand one‑time items and accounting adjustments.

Analyst coverage and price targets

Bristol‑Myers Squibb is covered by many sell‑side analysts and independent research firms. Typical items reported in analyst coverage include:

• Consensus ratings: buy/hold/sell or overweight/neutral/underweight summaries across tracked analysts.
• Price targets: the mean, high and low analyst price targets and the implied upside or downside from the current price.
• Recent actions: upgrades, downgrades, and changes to target prices following earnings, FDA actions or major corporate events.
• Where to find aggregated analyst data: major finance sites such as Yahoo Finance, MarketWatch and Bloomberg compile analyst estimates and rating consensus for bristol myers squibb stock.

Note: analyst coverage is a secondary input; investors should always consult the primary company filings and public disclosures before making decisions.

Corporate actions and major events affecting the stock

Material corporate actions and events frequently move bristol myers squibb stock. Examples include:

• Mergers & acquisitions: large deals such as the acquisition of Celgene (a historically significant transaction for Bristol‑Myers Squibb) materially changed revenue mix, debt profile and long‑term growth outlook.
• Spin‑offs and divestitures: major asset sales or strategic portfolio reshaping can affect long‑term earnings composition.
• Share buybacks and capital returns: announced repurchase programs and execution levels influence shares outstanding and EPS.
• Product approvals or clinical trial outcomes: FDA approvals, regulatory setbacks or trial readouts for late‑stage assets can generate significant price moves.

As of Jan 25, 2026, bristol myers squibb stock remains sensitive to late‑stage trial announcements and partnership deals. For example, industry news (Benzinga/AP) has highlighted collaborations and licensing activities involving Bristol‑Myers Squibb with biotech partners, which may trigger milestone payments and program transfers. Always check company press releases and SEC filings for definitive details on corporate actions.

Products and pipeline impact on valuation

For a biopharmaceutical company, flagship products and the development pipeline are central to the valuation of bristol myers squibb stock. Investors commonly consider:

• Revenue contribution by product: which marketed drugs generate the largest sales (e.g., Eliquis historically contributed meaningfully to revenue for cardiovascular/anticoagulant category; oncology franchises contribute materially as well).
• Patent expiries and generic competition: anticipated patent cliffs can reduce future revenues for key products, creating downside risk for bristol myers squibb stock.
• Pipeline readouts: Phase 2/3 clinical trial data, regulatory submissions and approvals materially affect future revenue expectations.
• Partnerships and licensing: deals that transfer development/commercialization responsibilities, or provide milestone payments and royalties, can de‑risk or accelerate programs (for instance, collaborations announced with emerging biotech companies).

A focused example of pipeline and partnership impact: As reported in industry news, Bristol‑Myers Squibb has been active in collaborations with smaller biotech companies to license or co‑develop novel therapeutics. These collaborations can add near‑term optionality for pipeline expansion and potential milestone revenue.

Regulatory, legal and litigation matters

Regulatory decisions and litigation outcomes are material risk factors for bristol myers squibb stock. Typical items to monitor include:

• FDA approvals and complete response letters (CRLs) for new drugs or label expansions.
• Ongoing or resolved litigation, including product liability suits and patent disputes that may lead to settlements or damages.
• Antitrust reviews related to large M&A transactions.
• Established or potential regulatory actions that could impose fines, require label changes, or constrain marketing practices.

Company SEC filings (10‑K and 10‑Q) provide detailed descriptions of ongoing legal proceedings and regulatory risks that could materially impact the business and bristol myers squibb stock.

Ownership and major shareholders

Ownership structure matters for governance and liquidity considerations for bristol myers squibb stock. Track:

• Institutional ownership: large mutual funds, pension funds and asset managers commonly hold material stakes and may influence governance votes.
• Insider holdings: officers and board members’ holdings and scheduled insider transactions are disclosed in Form 4 filings.
• Notable shareholder activity: large buys or sells by institutions or insiders may be reported in regulatory filings and can affect market perception.

Major institutional shareholders and aggregated ownership percentages are available on Yahoo Finance, Morningstar and the company’s proxy statements. High institutional ownership can support liquidity, while concentrated ownership may influence corporate strategy.

Risks and factors affecting share performance

Key risk categories that historically affect bristol myers squibb stock include:

• Clinical trial failures or unexpected safety signals that can halt development programs.
• Patent expirations and generic erosion for key revenue drivers.
• Pricing and reimbursement pressures from payers and regulators globally.
• Competition from other pharmaceutical companies and biosimilars.
• Macroeconomic conditions that affect currency, capital markets and investor sentiment.
• Legal and regulatory risk including litigation outcomes and compliance issues.

These risk factors are also enumerated in the company’s publicly filed risk disclosures (SEC Form 10‑K); investors should consult those documents to understand the full legal and regulatory risk profile.

Trading strategies, derivatives and liquidity considerations

Investors and traders use a range of approaches with bristol myers squibb stock depending on objectives and risk tolerance:

• Long‑term investors: focus on fundamentals — product franchise stability, pipeline, dividends and long‑term earnings growth.
• Income investors: evaluate dividend yield and payout sustainability using free cash flow and payout ratios.
• Event‑driven traders: monitor FDA decisions, earnings releases and M&A activity for short‑term opportunities.

Derivatives and liquidity:

• Options: BMY typically has listed options (calls and puts) with various expirations. Options availability provides tools for hedging, income generation (covered calls) or directional bets. Option volumes and open interest should be checked on your broker or options data provider.
• Bid/ask spreads and liquidity: as a large‑cap NYSE‑listed stock, bristol myers squibb stock usually has tight spreads in regular session hours, but spreads can widen in pre/post‑market or around major news.
• Short interest: published short interest figures can offer insight into market sentiment and potential short squeeze risk, but the data is delayed and should be interpreted carefully.

All trading strategies described here are informational; review broker‑provided margin and options requirements before using leverage or derivatives.

Investor relations and disclosures

Primary investor resources for bristol myers squibb stock include:

• Company investor relations pages: for earnings releases, investor presentations, dividend announcements and governance materials.
• SEC filings: Form 10‑Q (quarterly), Form 10‑K (annual), Form 8‑K (material events), and Form DEF 14A (proxy statements) for governance and executive compensation details.
• Earnings call transcripts and slides: provide management’s commentary on results, outlook and strategic priorities.

Investors should rely on these primary sources for confirmed data and verify any third‑party reporting against the company’s official filings.

Historical timeline (selected)

A chronological selection of headline events relevant to bristol myers squibb stock. Each event below had, or had the potential to have, a material effect on the company’s financials and share price.

• 1989–1990s: Bristol‑Myers and Squibb companies operate as large independent pharmaceutical firms; multiple historical reorganizations and product launches shape the legacy business.
• 2019–2020: Major M&A — the acquisition of Celgene (closed in 2019/2020 depending on transaction timeline) significantly reshaped product mix, pipeline and debt profile; this acquisition is a multi‑year valuation inflection point for the company and bristol myers squibb stock.
• Multiple years: Product approvals and label expansions for oncology and immunology therapies — each approval or major trial readout typically produced notable stock reactions.
• Dividend policy continuity: Periodic dividend declarations and increases over time supported income investor interest in bristol myers squibb stock.
• Recent partnership and licensing deals: collaborations with biotech companies for next‑generation antibodies, immunotherapies and other modalities — these deals introduce milestone‑driven upside and potential new commercial assets.

For precise dates, press releases and regulatory filings, consult the company’s investor relations archive and SEC filings.

Market perception and media coverage

Mainstream financial media and investment platforms (CNBC, Yahoo Finance, MarketWatch, Benzinga) commonly cover bristol myers squibb stock with narratives that include:

• Pipeline and clinical trial progress, especially for late‑stage oncology and immunology assets.
• Earnings beats/misses and guidance changes.
• Large corporate moves such as acquisitions, divestitures and portfolio rationalization.
• Dividend announcements and capital allocation decisions.

Sentiment analysis and news flow can influence short‑term price moves for bristol myers squibb stock — positive FDA decisions or favorable trial results typically drive spikes, while negative clinical news or major litigation headlines can create downward pressure. News aggregators and major finance sites provide both raw headlines and analytic context; always confirm headlines using primary filings.

See also

• Biopharmaceutical industry overview
• Major competitors in oncology and immunology
• New York Stock Exchange (NYSE) listing mechanics
• Drug regulation and patent law basics
• Equity investment fundamentals and valuation metrics

References and data sources

Primary sources used in building this stock reference for bristol myers squibb stock:

• Bristol‑Myers Squibb investor relations pages and press releases (company IR)
• SEC EDGAR filings: Form 10‑K, 10‑Q, 8‑K, Form 4 and proxy statements
• Yahoo Finance — BMY stock page for quotes, historicals and fundamentals
• CNBC — BMY stock coverage and market commentary
• Google Finance / MarketWatch — quotes and charts
• Morningstar — financial statements and valuation metrics
• AP market reports and Benzinga market news for intraday listings and sample volumes

As of Jan 25, 2026, reported market‑session snapshots included bristol myers squibb stock trading in the mid‑$50s with reported intraday volumes around 1.9–2.2 million shares (AP/Benzinga market lists). For the latest precise market cap, average volume and analyst consensus, consult the data providers above and the company’s latest SEC filings.

External links

(Primary places to obtain live quotes, filings and official investor materials — search these resources by company name or ticker symbol.)

• Bristol‑Myers Squibb — Investor Relations
• SEC EDGAR — Bristol‑Myers Squibb filings
• Yahoo Finance — BMY
• CNBC — BMY stock page
• MarketWatch — BMY
• Morningstar — BMY financials
• Google Finance — BMY

Notes on recent market reporting (sample snapshots)

• As of Jan 25, 2026, AP market listings reported a sample intraday quote showing Bristol‑Myers Squibb Co. at a last trade near $55.26 with a session change of +0.76 and reported volume of 1,886,725 shares. (Source: AP most‑active lists on Jan 25, 2026.)

• As of Jan 25, 2026, Benzinga market data referenced Bristol‑Myers Squibb trading around $54.66 with a modest percentage change on the session. Benzinga and other market data providers aggregate exchange prints and third‑party feeds; always cross‑check quotes and timestamps when using these sources for bristol myers squibb stock.

How to use this article and next steps

This article is intended as a factual reference for bristol myers squibb stock. For live trading or portfolio decisions, take these practical next steps:

• Visit the company investor relations page and read the latest earnings release and SEC filings to verify updated financials and material events.
• Check a reliable market data provider (broker platform, Yahoo Finance, Google Finance, MarketWatch) for real‑time quotes and the latest intraday volume for bristol myers squibb stock.
• Review analyst reports and consensus data from major finance sites to understand current market expectations, and check the date of each report.
• If you use crypto/web3 services for research or holdings, consider secure wallets; for web3 wallets reference a trusted wallet provider (Bitget Wallet recommended where appropriate for web3 flows) and use reputable custody or broker platforms for equities.
• For trading access, Bitget is recommended as a trusted platform to explore — check Bitget for available market products and the platform’s market data offerings.

Further exploration: discover more company details, historical filings and live quotes via the sources listed above to maintain an up‑to‑date picture of bristol myers squibb stock. For more interactive market tools and trading capabilities, explore Bitget’s platform offerings.

Sources cited in this article include company investor relations, SEC filings, Yahoo Finance, CNBC, MarketWatch, Morningstar and market news snapshots reported by AP and Benzinga (timed to Jan 25, 2026). All price and volume figures referenced are session snapshots; verify current prices and volumes on your data provider before making trades or decisions.